Inoveon | About Us

Mission
Inoveon is a premier medical services company that delivers solutions to detect, stage and monitor diseases affecting the eye — diabetic retinopathy, macular degeneration, and glaucoma. Inoveon's initial target is to help patients and their providers improve diabetic retinopathy care through Inoveon diagnostic service centers that are either independent or co-located in high volume diabetes care sites.

Overview
Founded in 1997, the Inoveon mission is to deliver high quality, comprehensive, digital services targeting major eye conditions including diabetic retinopathy, macular degeneration, glaucoma and others. Our patented process, which includes the 3DT imaging technology and iScore" Diabetes Eye Evaluation Service, improves the quality, economics, and medical outcomes of patients with diabetic retinopathy, a common complication of diabetes, and the leading cause of preventable blindness in the United States. All Inoveon technology has been validated to meet the "gold standard" for diabetic retinopathy established by the National Institute of Health. In March 2002, the peer-review publication Ophthalmology published the findings of an independent, masked, cross-sectional, clinical validation study of the 3DT technology on nearly three hundred adult patients with diabetes from the Chickasaw Nation's Carl Albert Indian Health Facility in Ada, Oklahoma. The study showed the 3DT achieved 98.3% sensitivity and 89.7% specificity for detection of vision threatening disease.

Opportunity
The Surgeon General has declared a "diabetes epidemic" in the United States. In addition, there is a very high probability that a diabetic will develop diabetic retinopathy (DR), which is the leading cause of blindness in America. Unfortunately, only about 40% of diabetics actually have their eyes examined annually. Recent studies show a growing underserved population who must rely on highly variable and subjective physician exams. For instance:

Of the 17 million diabetics in the United States, only 12 million are diagnosed.

There are 800,000 newly diagnosed cases each year, which are attributed to diet and obesity as well as demographic trends.

Products and Services
Diabetic Retinopathy Digital Disease Detection and Tracking Service (DR-3DT)
Inoveon offers a turnkey digital "gold standard" evaluation of diabetic retinopathy using high resolution, stereoscopic, seven-field retinal imaging. These data allow precise and accurate quantitative staging of diabetic retinopathy using the best protocols developed for clinical research. The convenience of Inoveon's service improves compliance with annual diabetic retinal evaluations and comprehensive reporting capabilities allow efficient diabetic retinopathy patient management by providers and health plans.

Technology
Inoveon 3DT service begins when a technician takes a non-invasive stereoscopic digital photograph of a diabetic patient's eyes. The 3DT proprietary technology platform then sends these images to an evaluation center in Nashville where non-physician experts supported by retinal specialists evaluate images and stage the disease. The 3DT software then transmits detailed results to the attending physician with follow-up and treatment recommendations based on medically approved standardized algorithms. While the market's current technology only produces three fields of view for an ophthalmologist, the Inoveon technology generates sevens fields of 30° stereoscopic color views. The Inoveon process is accurate, objective, quantifiable and reproducible — a diagnostic tool that has never been available to clinics, until now.

The Markets We Serve

Primary care physicians who treat diabetic patients

Endocrinologists

Diabetes disease management companies

Health plans seeking to improve the management of diabetic patients

Pharmaceutical and biomedical companies researching diabetes and diabetic retinopathy devices and therapies

Business Model
The National Institute of Health (NIH) gold standard for diagnosing diabetic retinopathy is 98.9%, however the current form of the NIH test is too expensive and cumbersome to deploy in a commercial clinical environment. Inoveon has developed a digital version of the NIH gold standard, which has been validated as 98.9% accurate and packaged for delivery to the broader primary care market in a cost effective and profitable manner.

The company will enter metropolitan service areas (MSAs) determined by demographics, concentration of diabetic population, number of appropriate doctors and the amount of clustering of those doctors. In areas with high potential, salespeople will educate doctors on the benefits of referring patients to an Inoveon site for testing. Once several doctors have signed up to refer patients, Inoveon will build-out a site convenient to their offices. The Inoveon Diagnostic Center will be a 400 square foot office for patient testing and data capture, equipped with one retinal imaging system linked to high-speed Internet access. One full-time and one part-time technician will manage the facility on a 40-hour-a-week basis.

© 2002 Inoveon Corporation

Mission
Inoveon is a premier medical services company that delivers solutions to detect, stage and monitor diseases affecting the eye — diabetic retinopathy, macular degeneration, and glaucoma. Inoveon's initial target is to help patients and their providers improve diabetic retinopathy care through Inoveon diagnostic service centers that are either independent or co-located in high volume diabetes care sites.

Overview
Founded in 1997, the Inoveon mission is to deliver high quality, comprehensive, digital services targeting major eye conditions including diabetic retinopathy, macular degeneration, glaucoma and others. Our patented process, which includes the 3DT imaging technology and iScore" Diabetes Eye Evaluation Service, improves the quality, economics, and medical outcomes of patients with diabetic retinopathy, a common complication of diabetes, and the leading cause of preventable blindness in the United States. All Inoveon technology has been validated to meet the "gold standard" for diabetic retinopathy established by the National Institute of Health. In March 2002, the peer-review publication Ophthalmology published the findings of an independent, masked, cross-sectional, clinical validation study of the 3DT technology on nearly three hundred adult patients with diabetes from the Chickasaw Nation's Carl Albert Indian Health Facility in Ada, Oklahoma. The study showed the 3DT achieved 98.3% sensitivity and 89.7% specificity for detection of vision threatening disease.

Opportunity
The Surgeon General has declared a "diabetes epidemic" in the United States. In addition, there is a very high probability that a diabetic will develop diabetic retinopathy (DR), which is the leading cause of blindness in America. Unfortunately, only about 40% of diabetics actually have their eyes examined annually. Recent studies show a growing underserved population who must rely on highly variable and subjective physician exams. For instance:

Of the 17 million diabetics in the United States, only 12 million are diagnosed.

There are 800,000 newly diagnosed cases each year, which are attributed to diet and obesity as well as demographic trends.

Products and Services
Diabetic Retinopathy Digital Disease Detection and Tracking Service (DR-3DT)
Inoveon offers a turnkey digital "gold standard" evaluation of diabetic retinopathy using high resolution, stereoscopic, seven-field retinal imaging. These data allow precise and accurate quantitative staging of diabetic retinopathy using the best protocols developed for clinical research. The convenience of Inoveon's service improves compliance with annual diabetic retinal evaluations and comprehensive reporting capabilities allow efficient diabetic retinopathy patient management by providers and health plans.

Technology
Inoveon 3DT service begins when a technician takes a non-invasive stereoscopic digital photograph of a diabetic patient's eyes. The 3DT proprietary technology platform then sends these images to an evaluation center in Nashville where non-physician experts supported by retinal specialists evaluate images and stage the disease. The 3DT software then transmits detailed results to the attending physician with follow-up and treatment recommendations based on medically approved standardized algorithms. While the market's current technology only produces three fields of view for an ophthalmologist, the Inoveon technology generates sevens fields of 30° stereoscopic color views. The Inoveon process is accurate, objective, quantifiable and reproducible — a diagnostic tool that has never been available to clinics, until now.

The Markets We Serve

Primary care physicians who treat diabetic patients

Endocrinologists

Diabetes disease management companies

Health plans seeking to improve the management of diabetic patients

Pharmaceutical and biomedical companies researching diabetes and diabetic retinopathy devices and therapies

Business Model
The National Institute of Health (NIH) gold standard for diagnosing diabetic retinopathy is 98.9%, however the current form of the NIH test is too expensive and cumbersome to deploy in a commercial clinical environment. Inoveon has developed a digital version of the NIH gold standard, which has been validated as 98.9% accurate and packaged for delivery to the broader primary care market in a cost effective and profitable manner.

The company will enter metropolitan service areas (MSAs) determined by demographics, concentration of diabetic population, number of appropriate doctors and the amount of clustering of those doctors. In areas with high potential, salespeople will educate doctors on the benefits of referring patients to an Inoveon site for testing. Once several doctors have signed up to refer patients, Inoveon will build-out a site convenient to their offices. The Inoveon Diagnostic Center will be a 400 square foot office for patient testing and data capture, equipped with one retinal imaging system linked to high-speed Internet access. One full-time and one part-time technician will manage the facility on a 40-hour-a-week basis.

© 2002 Inoveon Corporation